Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome (IRIS)
This study has been completed.
First Posted: March 20, 2012
Last Update Posted: January 14, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
University Hospital Tuebingen
Albert Schweitzer Hospital
Information provided by (Responsible Party):
S. Janssen, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
The objective of this project is to determine clinical and biological predictors of Immune Reconstitution Inflammatory Syndrome (IRIS) occurrence in HIV infected patients who are started on antiretroviral therapy (ART), and to obtain more insight into the pathogenesis of this syndrome. The investigators will prospectively study HIV infected patients in Sub Saharan Africa who will be initiated on ART and are at risk to develop IRIS in all its different appearances. In these patients, the investigators will assess the value of clinical features and plasma biomarkers to predict IRIS, and the investigators will obtain insight into which inflammatory pathways become activated during IRIS. This project will provide novel knowledge about this clinically highly relevant healthcare problem in a resource poor setting, namely in Lambaréné, Gabon, in the Central African rainforest belt. In Gabon little research has been done in the field of HIV. The epidemiological pattern of IRIS in Gabon will be described. Promising putative plasma biomarkers will be validated for their use in daily practice.
Immune Reconstitution Inflammatory Syndrome
||Observational Model: Cohort
Time Perspective: Prospective
||Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome in Lambaréné, Gabon
Primary Outcome Measures:
Biospecimen Retention: Samples Without DNA
Secondary Outcome Measures:
Plasma, Paxgene RNA tubes and urine
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||February 2014 (Final data collection date for primary outcome measure)
Adult patients starting anti retroviral therapy for the first time